Diese Website verwendet Cookies, damit wir dir die bestmögliche Benutzererfahrung bieten können. Cookie-Informationen werden in deinem Browser gespeichert und führen Funktionen aus, wie das Wiedererkennen von dir, wenn du auf unsere Website zurückkehrst, und hilft unserem Team zu verstehen, welche Abschnitte der Website für dich am interessantesten und nützlichsten sind.
ACXIT ADVISED THE SHAREHOLDERS OF GERMAN ANALYTICAL CRO BIOASSAY GMBH ON THE SALE TO REACTION BIOLOGY CORP.
Frankfurt am Main, 08 December 2022. ACXIT – A Stifel Company acted as exclusive sellside advisor to the shareholders of Bioassay Labor für biologische Analytik GmbH (“Bioassay”), including its wholly-owned subsidiary, Peptide Specialty Laboratories GmbH (“PSL”), located in Heidelberg/Germany, on the sale of the company to Reaction Biology Corp., based in Malvern, PA.
This deal adds another reference transaction to ACXIT’s strong track record in the Healthcare and Life Sciences sector and positions the group well to serve its corporate customers as well as financial sponsors on transactions in the fast growing Pharma Services market, including analytical CRO and CDMO markets.
For further information please find below the press release issued by Reaction Biology.
Reaction Biology Acquires Bioassay GmbH, Increasing Large Molecule Capabilities Within Its Robust Portfolio of Drug Discovery and Development Services
– Bioassay GmbH, an Independent Contract Laboratory, Specializes in the Development, Validation and Routine Performance of Bioanalytical Assays
– Transaction Includes Acquisition of Bioassay GmbH Subsidiary, Peptide Specialty Laboratories GmbH, a Provider Specializing in the Synthesis and Production of Customized Peptides and Specific Antibodies
– Transaction Adds Large Molecule Talent and GMP and GLP Accredited Equipment and Facilities
Malvern, PA – December 1, 2022 – Reaction Biology Corporation (“Reaction”), an industry-leading provider of drug discovery and development services, today announced that the Company has closed on a definitive agreement for Reaction to acquire Bioassay Labor für biologische Analytik GmbH (“Bioassay”), including its wholly-owned subsidiary, Peptide Specialty Laboratories GmbH (“PSL”), located in Heidelberg, Germany.
Bioassay offers Good Manufacturing Practices (GMP) accredited potency assays and functional bioassays, Good Laboratory Practices (GLP) compliant services, and through PSL, peptide synthesis services, including peptide-specific antibody production and neoantigen synthesis. Personnel, equipment, and facilities from the acquired companies will expand Reaction’s presence in Germany, while also enabling its global customers to leverage Bioassay’s expansive portfolio of regulated clinical and commercial services.
“Market demand is increasing globally for large molecule services as biopharmaceutical companies search for new treatment options for patients suffering with cancer and other serious diseases,” said John H. Johnson, Chief Executive Officer of Reaction Biology. “This transaction enables Reaction Biology to add Bioassay GmbH’s impressive clinical phase and post-approval infrastructure, which includes large molecule capabilities, as well as its GMP and GLP accreditations, to our expanding suite of drug discovery and development services. We can now provide our customers with even broader offerings to meet their research and development goals.”
Dr. Sven Cords, Managing Director and Chief Operating Officer, and Dr. Axel Hohenstein, Managing Director and Chief Scientific Officer, of Bioassay GmbH jointly commented: “Reaction’s commitment to high quality science and reputation for providing customers a personalized and collaborative research experience were instrumental in our decision to join this outstanding company. The infrastructure and resources gained from this acquisition provide us with an even stronger platform from which to expand our bioanalytical capabilities and grow our customer base, all while continuing to deliver gold standard quality services. Along with our colleagues, we look forward to joining Reaction and starting this exciting new phase of shared growth.”
GMP and GLP are accreditations imposed by regulatory bodies such as the FDA and EMA for compliance in the stages of design, testing, manufacturing, and the distribution of healthcare products. They ensure proper protocols and process validation for producing replicable results and adhering to industry standards.
White & Case LLP served as Reaction’s legal counsel for the transaction.
ACXIT Capital Partners, a Stifel Company, and Goodwin Procter LLP, served as Bioassay GmbH’s financial advisor and legal counsel, respectively.
About Reaction Biology
Founded in 2001, Reaction Biology is a global contract research organization (CRO) that provides drug discovery and development services to biopharmaceutical customers worldwide. Reaction specializes in supporting research goals with capabilities that include protein and peptide production, biochemical and biophysical assays, high throughput screening, exploratory toxicology, biomarker discovery tools, and an extensive array of cell-based and pharmacological assays modelling various diseases. Reaction also provides Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) analytical and functional bioassays for testing potency, efficacy, and safety of large biological molecules, enabling clinical and commercial manufacturing batch release. Reaction has helped to advance many of its customers’ molecules through discovery and development pipeline stages into later clinical phases. These molecules may ultimately benefit patients living with cancer and other serious diseases. Reaction maintains one of the largest panels of kinase assays in the world with over 750 unique assays and performs more than 5,000 client projects annually with its over 2,000 validated assays.
Reaction has laboratory facilities in Malvern, PA, Hershey, PA, Freiburg, Germany, and Heidelberg, Germany. For more information, visit ReactionBiology.com and follow us on Twitter @ReactionBiology and on LinkedIn.
Transaction Team ACXIT – A Stifel Company
Thomas Klack, Managing Director
Klaus Nestler, Managing Director
Daniel Rival, Director
Ömer-Enes Dursun, Associate
Daniel Lerch, Analyst
ACXIT Capital Holding GmbH
Bockenheimer Landstrasse 24
60323 Frankfurt am Main
Tel: +49 69 247 414 213